BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
IPO Year: 2018
Exchange: NASDAQ
Website: bioxceltherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/21/2024 | $9.00 → $4.00 | Buy → Neutral | UBS |
| 8/15/2023 | $40.00 → $4.00 | Buy → Neutral | Mizuho |
| 7/17/2023 | Buy → Neutral | Guggenheim | |
| 3/10/2023 | $20.00 → $22.00 | Buy → Hold | Jefferies |
| 12/1/2022 | $16.00 | Sell → Neutral | Goldman |
| 7/7/2022 | $19.00 | Buy | Mizuho |
| 4/6/2022 | $80.00 | Buy | BofA Securities |
| 2/16/2022 | $88.00 → $25.00 | Buy | UBS |
| 11/15/2021 | $55.00 → $24.00 | Buy → Sell | Goldman Sachs |
| 6/28/2021 | $176.00 → $140.00 | Buy | HC Wainwright & Co. |
8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)
SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)
10-Q - BioXcel Therapeutics, Inc. (0001720893) (Filer)
8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
S-8 - BioXcel Therapeutics, Inc. (0001720893) (Filer)
8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
424B5 - BioXcel Therapeutics, Inc. (0001720893) (Filer)
10-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form
UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously
Mizuho downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously
Guggenheim downgraded BioXcel Therapeutics from Buy to Neutral
Jefferies downgraded BioXcel Therapeutics from Buy to Hold and set a new price target of $22.00 from $20.00 previously
Goldman upgraded BioXcel Therapeutics from Sell to Neutral and set a new price target of $16.00
Mizuho initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $19.00
BofA Securities reiterated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $80.00
UBS reiterated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $25.00 from $88.00 previously
Goldman Sachs downgraded BioXcel Therapeutics from Buy to Sell and set a new price target of $24.00 from $55.00 previously
HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $140.00 from $176.00 previously